No Vaccine Related Serious Adverse Events (SAEs) reported to date On track to report topline data from two Phase 2…
Congressman Peters (D-CA-50) tours Wateridge manufacturing site in San Diego and celebrates Maravai’s impact in COVID vaccine productionSAN DIEGO, June…
Figure 1 Sorrento Therapeutics, Inc. Figure 2 Sorrento Therapeutics, Inc. Figure 3 Sorrento Therapeutics, Inc. CHICAGO, June 05, 2023 (GLOBE…
IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5 of 7 (71%) of patients…
MALVERN, Pa., June 05, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused…
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were…
Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC) formulation combination biweekly regimen showed…
- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion…
BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first…
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndromeA high proportion of patients had…